** Brokerage H.C. Wainwright starts coverage on drugmaker Ionis Pharmaceuticals IONS.O with "buy" rating and a PT of $45
** Brokerage sees upside in IONS' pending commercial launches, including Tryngolza for lowering triglycerides and Wainua for transthyretin-mediated amyloidosis (ATTR)
** Brokerage estimates that Tryngolza could serve 2.3 million patients in the U.S. and become a growth driver for the company, potentially generating $1.8 billion in sales by 2033
** 17 out of 26 brokerages rate the stock "buy" or higher, 8 rate "hold" and 1 rate "sell" and their median PT is $60 as per LSEG data
** As of last close, IONS stock down 22.5% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.